Driving Growth through
Advanced API Research
Research and Development (R&D) lies at the core of Concord’s growth, driven by a team of highly skilled scientists and supported by advanced technologies. Our sustained R&D efforts have expanded the product portfolio, enabling us to develop unique and complex APIs across therapeutic areas such as oncology, immunosuppressants, antibiotics, and antifungals. The API R&D division specializes in fermentation, semi-synthetic, and synthetic processes that comply with stringent regulatory standards of the USFDA, EU GMP, Japan PMDA, Brazilian FDA, and other emerging markets, reinforcing Concord Biotech’s position as a trusted leader in Global Healthcare.